eficacia en un ensayo de fase 3
VACCINATION STUDY
A recent study has shown that the use of a vaccine against the SINCitial virus can be effective in a third stage of a clinical trial. The study was conducted by the University of Texas at Austin and was funded by the federal government. The purpose of the study was to evaluate the safety and efficacy of a vaccine against the SINCitial virus in a clinical trial of patients with severe acute respiratory syndrome (SARS).
The study enrolled patients who were admitted to a hospital with SARS and who were also infected with the SINCitial virus. Patients were given a vaccine against the SINCitial virus, or a placebo, or a combination of the two. The study was conducted over a period of three months and the results were published in the journal MIND.
The study found that the vaccine was safe and effective. The study participants were observed to have a significant decrease in the number of days requiring treatment for respiratory Diseases, including SARS, during the study. The study also found that the vaccine was effective in reducing the incidence of respiratory infection in the study population.
The study is a large, prospective study that is still ongoing. The study is important because it demonstrates that the use of a vaccine against the SINCitial virus can be effective in a third stage of a clinical trial. This is significant because it could lead to the development of a more effective and affordable SARS vaccine.